Annual Cash & Cash Equivalents:
$594.35M+$202.78M(+51.79%)Summary
- As of today, RXRX annual cash & cash equivalents is $594.35 million, with the most recent change of +$202.78 million (+51.79%) on December 31, 2024.
- During the last 3 years, RXRX annual cash & cash equivalents has risen by +$309.23 million (+108.46%).
- RXRX annual cash & cash equivalents is now at all-time high.
Performance
RXRX Cash and Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Cash & Cash Equivalents:
$528.22M+$24.69M(+4.90%)Summary
- As of today, RXRX quarterly cash & cash equivalents is $528.22 million, with the most recent change of +$24.69 million (+4.90%) on June 30, 2025.
- Over the past year, RXRX quarterly cash & cash equivalents has increased by +$52.09 million (+10.94%).
- RXRX quarterly cash & cash equivalents is now -17.85% below its all-time high of $642.97 million, reached on June 30, 2021.
Performance
RXRX Quarterly Cash & Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RXRX Cash and Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +51.8% | +10.9% |
| 3Y3 Years | +108.5% | +2.1% |
| 5Y5 Years | +750.5% | - |
RXRX Cash and Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +108.5% | -11.6% | +76.3% |
| 5Y | 5-Year | at high | +750.5% | -17.9% | +141.1% |
| All-Time | All-Time | at high | +750.5% | -17.9% | +141.1% |
RXRX Cash and Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $528.22M(+4.9%) |
| Mar 2025 | - | $503.53M(-15.7%) |
| Dec 2024 | $594.35M(+51.8%) | $597.39M(+39.2%) |
| Sep 2024 | - | $429.20M(-9.9%) |
| Jun 2024 | - | $476.12M(+59.0%) |
| Mar 2024 | - | $299.52M(-24.1%) |
| Dec 2023 | $391.56M(-28.8%) | $394.80M(+1.3%) |
| Sep 2023 | - | $389.58M(-4.8%) |
| Jun 2023 | - | $409.19M(-13.8%) |
| Mar 2023 | - | $474.46M(-13.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $549.91M(+92.9%) | $551.19M(+20.7%) |
| Sep 2022 | - | $456.74M(-11.7%) |
| Jun 2022 | - | $517.34M(-12.7%) |
| Mar 2022 | - | $592.63M(+14.4%) |
| Dec 2021 | $285.12M(+8.8%) | $518.11M(-12.1%) |
| Sep 2021 | - | $589.14M(-8.4%) |
| Jun 2021 | - | $642.97M(+193.4%) |
| Mar 2021 | - | $219.13M(-16.4%) |
| Dec 2020 | $262.13M(+275.1%) | - |
| Dec 2020 | - | $262.13M |
| Dec 2019 | $69.88M | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all-time high annual cash & cash equivalents for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all-time high quarterly cash & cash equivalents for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of RXRX is $594.35M
What is the all-time high annual cash & cash equivalents for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $594.35M
What is Recursion Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, RXRX annual cash & cash equivalents has changed by +$202.78M (+51.79%)
What is Recursion Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of RXRX is $528.22M
What is the all-time high quarterly cash & cash equivalents for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $642.97M
What is Recursion Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, RXRX quarterly cash & cash equivalents has changed by +$52.09M (+10.94%)